This article is more than 5 years old. Information may no longer be current.
Lupus Foundation, PhRMA report finds more than 300 medicines in development to treat autoimmune diseases
Click Here to Manage Email Alerts
The Pharmaceutical Research and Manufacturers of America and the Lupus Foundation of America released a report that showed biopharmaceutical research companies in the United States have 311 medicines and vaccines in clinical trials or pending review by the FDA for patients with autoimmune disease.
According to the report, the medicines in development include 76 for autoimmune types of arthritis, including juvenile idiopathic arthritis; 58 for inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; 39 for lupus; 34 for type 1 diabetes; and 32 for multiple sclerosis. Specifically, the report notes several monoclonal antibody medicines are in development for the treatment of lupus, psoriasis and Sjögren’s syndrome, while researchers are studying medicines already approved to treat one autoimmune disease for applicability in treating additional diseases.
“The question of why the immune system in some people attacks healthy cells remains top of mind for biopharmaceutical researchers striving to discover new treatments and cures for the 23.5 million Americans affected by an autoimmune disease,” Stephen J. Ubl, president and chief executive officer of Pharmaceutical Research and Manufactures of America, said in a press release. “While there are a number of challenges in diagnosing and treating these diseases, the significant progress that has been made in the last decade provides hope for the future.”
Reference:
https://prnmedia.prnewswire.com/news-releases/393101821.html?tc=PRNJ_email_plaintext_headlines